What We Do
Bernstein lab pursues a systems-level, molecular understanding of chromatin structure and the epigenetic regulation of cellular state, and how these systems go awry in disease.More
Brad delivers a seminar sponsored by the DF/HCC Connect:Science seminar series and the Leukemia & Lymphoma Society. In the midst of the Covid-19 pandemic, researchers continue to engage.
Flavahan, Drier et al. publish in Nature how epigenetic alterations drive oncogenic programs in SDH-deficient GISTs
You can read the study in Nature
Brad was interviewed for the ACS Theory lab podcast last week! “Cancer has classically been thought of as a genetic disease, but…”
We develop cutting edge technologies – many of which utilize sequencing-based technology – to both map and perturb chromatin state, with a focus on single cells, single molecules, and large scale perturbations with small molecules and CRISPR screens. Our current projects focus on: High throughput low input and single cell transcriptomic and epigenomic mapping Single … Continued
Genes encoding chromatin regulators are frequently mutated in human cancer. In specific cases, these alterations appear to be major drivers of the malignant state. In addition, although cancer is typically thought of as a genetic disease, the importance of epigenetic aberrations and epigenetic deregulation is becoming increasingly clear through a convergence of findings, in addition … Continued
The group investigates mechanisms by which chromatin, transcription factors (TFs) and interacting regulatory sequences control gene activity, poising and repression.
Chromatin regulators, such as the Polycomb and trithorax complexes, play critical roles in controlling the expression and potential of genes during development. We identified a novel chromatin structure, termed bivalent domains, that is subject to simultaneous regulation by Polycomb repressors and trithorax activators. Bivalent domains appear to keep developmental regulator genes poised in pluripotent embryonic … Continued